ADx NeuroSciences has signed a collaborative R&D agreement with the Japanese Nipro Corporation. The companies will jointly develop next-generation in vitro diagnostics for Alzheimer’s disease. The agreement was officially signed during the Belgian Royal State Visit to Japan.

Japan has the oldest population in the world and the country counts more than 4.6 million Alzheimer patients. Japanese pharmaceutical companies have Alzheimer’s drug development high on their priority list and invest heavily in solutions for the disease. Nipro has a long standing experience in the development and commercialization of diagnostics and treatments of Alzheimer’s. Together with ADx, the company will now look into the development of Point Of Care diagnostic devices.

Koen Dewaele, CEO ADx NeuroSciences: “This collaboration is yet another confirmation of our successful business model. ADx is the global number 1 provider of high quality antibodies for diagnostics of neurodegenerative diseases like Alzheimer’s and Parkinson’s.”

Yoshida Hiroshi, Director R&D development Nipro: “We know the people at ADx have a lot of expertise in the field of Alzheimer’s. Their valuable antibodies help us to develop state-of-the-art Alzheimer’s diagnostics.”

Read the full press release here.